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antiviral immune responses and (2) the ability to reinfect 
those with prior immunity. The latter phenotype strongly 
implies that, if HCMV can overcome prior immunity to 
initiate a new infection, it is likely irrelevant whether prior 
immunity derives from prior infection or prior vaccina-
tion. Both phenotypes are unified by the extensive devotion 
of the HCMV coding repertoire (~50 %) to viral proteins 
that modulate host cell signaling, trafficking, activation, 
antigen presentation, and resistance to apoptosis. Col-
lectively, these viral proteins are the likely reason for the 
high barrier to success for the 4-decade effort to design an 
HCMV vaccine, and they represent the viral proteins that 
make HCMV be the virus that it is. James Hanshaw wrote 
in 1971 that, based on a 15-year retrospective of congeni-
tal HCMV cases, “… any thoughtful program designed at 
prevention or treatment deserves consideration”. Draw-
ing upon natural history data from the nonhuman primate 
model of HCMV persistence and pathogenesis, a “thought-
ful program” is put forth that HCMV immune-modulating 
proteins should be considered as vaccine candidates.
Keywords Cytomegalovirus vaccine · Viral 
interleukin-10 · Immune modulation · Viral natural history
Introduction
Some of the earliest observations of CMV infections in 
nonhuman primates were remarkably prescient about con-
temporary CMV research occurring eight decades later 
(Table 1). Three years after it was demonstrated (1926) that 
the salivary gland agent of guinea pig was a virus that stim-
ulated pathognomonic intracellular inclusions in infected 
cells, similar inclusion-bearing cells were observed in 
rhesus macaques acutely infected with poliovirus [1]. 
Abstract The partial successes of the Phase 2 gB-based 
vaccine trials for HCMV highlight the very real likeli-
hood that vaccine-mediated induction of antibodies that 
neutralize the fusion pathway of fibroblast infection is 
not sufficient as a singular strategy to confer protective 
efficacy against primary HCMV infection. Alternative 
strategies that serve as adjuncts to gB-based vaccines are 
likely required to target different aspects of the complex 
lifecycle of HCMV infection. There has been consider-
able recent interest in targeting the gH/gL/UL128/UL130/
UL131 pentamer complex (gH/gL-PC) to neutralize the 
endocytic pathway of HCMV infection of epithelial and 
endothelial cells. Since both cell types are critical during 
primary mucosal infection, intrahost spread, and shedding 
of HCMV in an infected host, the gH/gL-PC represents a 
high-value target for vaccination to interrupt the HCMV 
lifecycle. The natural history of HCMV is exceedingly 
complex and incompletely resolved, and the protective 
efficacy generated by gH/gL-PC remains to be validated in 
clinical trials. Yet, there are salient aspects of its lifecycle 
that offer clues about how other novel vaccine strategies 
can be targeted to especially susceptible parts of the viral 
proteome to significantly disrupt HCMV’s ability to infect 
susceptible hosts. In particular, the protracted evolution of 
Herpesvirales has endowed HCMV with two remarkable 
properties of its natural history: (1) lifelong persistence 
within immune hosts that develop extraordinarily large 
This article is part of the Special Issue on Cytomegalovirus.
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Inclusion-bearing cells were observed in the majority of 
study animals. The authors concluded that the intracellu-
lar lesions, phenotypically consistent with those described 
in guinea pigs, were unrelated to poliovirus infection. The 
authors further noted that cytomegalic cells were often 
associated with mixed lymphocytic infiltrates but some-
times were unaccompanied by any signs of a local inflam-
matory response. The occasional absence of inflammatory 
cells localized to a cytomegalic cell that we now recognize 
as one expressing the full complement of viral proteins is 
consistent with viral modulation of host immune responses 
in the microenvironment of that infected cell. These obser-
vations were extended 2 years later in 1931 by Covell [2] 
who concluded that the lesions, found in epithelial cells 
of multiple tissues, were not associated with clinical signs 
of infection and were “caused by some virus of low viru-
lence”. Finally, Cowdry and Scott [3] noted that treatment 
of macaques with irradiated ergosterol, a sterol found in the 
cell membranes of fungi and yeasts, stimulated increased 
numbers of cytomegalic cells compared with untreated ani-
mals. The authors concluded that treatment with ergosterol 
“may have activated or intensified a process already latent 
in the kidneys” and that the “association between persis-
tence of inclusions and presence of active virus may be 
stressed”.
Thus, within 10 years of the recognition that a filter-
able agent of animals induced cytomegalic cells that were 
identical in description to those identified in infants who 
died shortly after birth [4, 5], the essence of CMV natural 
history was set forth. By the end of 1935, CMV was char-
acterized as a ubiquitous virus with a broad tissue tropism 
that stimulates protective immune response in infected 
hosts, resulting in low pathogenic potential, yet persists in 
that same immune host, in part through establishment of 
and reactivation from latency, and in part through immune 
modulation.
This duality of CMV’s effect on the host immune sys-
tem, stimulating immune responses that protect against 
clinical disease yet fail to clear persistent and active virus, 
represents something of a Gordian knot that requires 
thinking outside of the box to solve the underlying conun-
drum. Much as Winston Churchill recognized in 1939 that 
there was a key to predicting Russia’s actions (“a riddle 
wrapped in an mystery inside an enigma”), there, too, is a 
key to the seeming paradoxes of CMV natural history. For 
Churchill, the key was Russian national interests.
For CMV, the key is likely found within CMV and Her-
pesvirales evolution from a progenitor herpesvirus, which 
has been estimated to have arisen 200–400 M years ago 
[6, 7]. As obligate intracellular pathogens, physical, innate, 
and adaptive barriers to infection represent exceedingly 
high thresholds for a virus to enter a cell and subsume host 
machinery to generate progeny virions that can spread both 
within the infected host and between hosts. Given that her-
pesviruses infect countless vertebrate species, and at least 
one invertebrate species, the 200–400 M years of inter-
vening time since the progenitor herpesvirus represents 
200–400 M years of Darwinian selection, and that for every 
variant that arose, “rejecting that which is bad, preserv-
ing and adding up all that is good; silently and insensibly 
working [at] the improvement of each organic being” [8]. 
Put another way, an order of viruses that has evolved on a 
geologic timescale (since Devonian to Jurassic periods) has 
to be exceedingly good at what it does to still be around to 
infect us, let alone be fascinating topics of research.
While all herpesviruses establish and maintain lifelong 
persistence within infected hosts, the virus–host relation-
ship between HCMV and infected humans appears to be 
unique among the herpesviruses, and definitely unlike any 
other characterized pathogen–host interaction. The pio-
neering study of Sylwester et al. [9], in which the T cell 
response to the HCMV proteome was quantified, revealed 
that there is an extraordinarily large devotion of the T cell 
repertoire (~10 % of both memory CD4+ and CD8+ T 
cells) to a single pathogen. This massive T cell response is 
undoubtedly essential for ensuring that HCMV is a virus 
with low pathogenic potential in immune competent hosts. 
This interpretation is substantiated by the fact that impair-
ment of immune functionality, such as that following iat-
rogenic immunosuppression or HIV–AIDS, is associated 
with dramatically increased risks of HCMV morbidity and 
mortality. The T cell response to HCMV may have been the 
result of an evolutionary arms race with the coding sophis-
tication within the HCMV genome. Between 56 and 72 % 
of the Towne and AD169, open reading frames (ORF) can 
be individually deleted, respectively, without impairing 
replication in fibroblasts [10, 11]. The CMV family has 
evolved redundant and/or overlapping functions for many 
viral proteins, thus enabling the deletion of one ORF with-
out compromising replicative fitness within fibroblasts. 
However, another interpretation of ORF being dispensable 
for replication in cultured cells is that they are indispensa-
ble for viral infection within the host. While functions for 
Table 1  Early recognition of key features of CMV natural history in 
nonhuman primates
Phenotype Year Reference
Inclusion bodies 1929 [1]
Ubiquitous
Immune modulation
Low virulence 1931 [2]
Broad tissue tropism
Reactivation from latency 1935 [3]
Persistence
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many ORF remain to be defined, those ORF, which have 
been characterized, broadly target multiple aspects of 
innate and adaptive effector functions [12, 13], and the rea-
sonable conclusion is that HCMV is “armed for bear” when 
it comes to countering almost every aspect of host immu-
nity. And these viral immune-modulating proteins have 
conferred a remarkable ability on HCMV.
Whereas viruses such as HIV and influenza undergo 
genetic drift as a mechanism for emergence of immune 
escape variants, this is not a strategy employed by HCMV 
to counter host effector functions. It does not appear that 
there have been descriptions of immune escape variants for 
HCMV. This stands in marked contrast to the occasionally 
rapid emergence of drug-resistant variants following anti-
viral treatments. The simplest interpretation is that HCMV 
never had to evolve other strategies to counter anti-HCMV 
drug regimens that are very recent in the context of herpes-
virus evolution. In contrast, herpesviruses in general, and 
CMV in particular, evolved in the context of evolutionarily 
ancient innate adaptive immune systems, and in the con-
text of the more recent adaptive immune systems and an 
extensive array of haplotypes. Taken together, the arsenal 
of HCMV-encoded immune-modulating proteins obviated 
the need to resort to genetic drift to counter host immunity. 
By extension then, this class of viral proteins defines the 
essence of HCMV natural history, and abrogation of their 
functions should significantly impair HCMV’s ability to 
successfully complete in life cycle within an infected host. 
Accordingly, the hypothesis is presented that immune-mod-
ulating proteins of HCMV should be considered as vaccine 
targets to serve as adjuncts to the current paradigms of neu-
tralizing viral attachment to susceptible cells. This review 
will primarily draw upon work in the nonhuman primate 
model of HCMV persistence and pathogenesis involv-
ing infection of rhesus macaques (Macaca mulatta) with 
rhesus CMV (RhCMV), together with notable findings of 
HCMV that highlight the importance of immune modula-
tion in primate CMV natural history.
Manipulation of the IL‑10 signaling pathway
A central feature of microbial pathogenesis, including 
CMV, is that pathogens have evolved a myriad of viru-
lence strategies involving attenuation, exploitation, and/
or cooptation of normally protective immune functions to 
enable the completion of the pathogen’s life cycle within 
the host and dissemination to the next susceptible host. 
While there are pathogen-specific mechanisms for alter-
ing pathogen–host interactions, there are also common 
immune-modulating pathways shared among evolutionarily 
diverse pathogens. In particular, a large number of viruses, 
protozoa, pathogenic and commensal bacteria, helminths, 
and fungi all utilize manipulation of the interleukin-10 (IL-
10) signaling pathway as part of microbial natural history 
[14]. Given that IL-10 is a master immune regulator with 
pleiotropic effects on multiple cell types [15], it is no sur-
prise that pathogens target this singular pathway to subvert 
protective effector functions. One emerging theme is that 
pathogens and commensal bacteria have coopted IL-10 
signaling to enable states of immune tolerance, immune 
suppression, and immune evasion, strategies that are par-
ticularly salient for those pathogens that establish lifelong 
persistence [16, 17].
The vast majority of pathogens that exploit the IL-10 
signaling pathways have evolved strategies that upregulate 
IL-10 expression by host cells, although the precise mech-
anism by how this occurs remains incompletely resolved. 
However, certain members of Herpesviridae and Poxviri-
dae transduced cellular IL-10 (cIL-10) genes at some point 
in their evolution and now express the viral IL-10 (vIL-10) 
orthologs in the context of viral infection [18]. [NOTE: 
vIL-10 is used as a generic term for the cIL-10 ortholog 
encoded within viral genomes.] Identification of a multi-
ply sliced vIL-10 transcript in RhCMV (rhcmvIL-10) was 
a serendipitous discovery. Based on the presence of the 
rhcmvIL-10 gene within the RhCMV genome, reanaly-
sis of the AD169 coding content revealed that the original 
annotation for potential ORF within the AD169 sequence 
[19] missed the presence of the HCMV-encoded cmvIL-10 
(UL111a) due to the sizes of the three exons of cmvIL-10 
falling below the 100 amino acid threshold for identify-
ing ORF [20]. Both HCMV- and RhCMV-encoded vIL-10 
orthologs are about as divergent from the cIL-10 proteins 
of their host (27 and 25 % identity, respectively), as they 
are from each other (31 % identity). Sequencing of the vIL-
10 gene from multiple strains indicates that the vIL-10 pro-
tein is very stable for intraspecies comparisons of HCMV 
or RhCMV strains [21]. cmvIL-10 and rhcmvIL-10 do not 
represent a hyper-variable region within the HCMV and 
RhCMV genomes. The extensive drift from the cIL-10 pro-
teins of their respective host species strongly alludes to the 
functional dominance of this viral protein in HCMV and 
RhCMV natural histories.
Whatever selective pressures there were that might 
account for the current sequence divergence of cmvIL-10 
and rhcmvIL-10 from cIL-10, the end result is that what 
was once a host “self”, non-immunogenic protein expressed 
during progenitor primate CMV infection has diverged to 
become a highly immunogenic protein. RhCMV vIL-10 
stimulates robust titers of both rhcmvIL-10-binding and 
rhcmvIL-10-neutralizing antibodies in RhCMV-infected 
macaques [22]. Antibody responses to cmvIL-10 have also 
been reported in HCMV-infected humans [23]. One simple 
interpretation is that the positive selective advantage con-
ferred by retaining only 25–27 % sequence identity with 
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the host cIL-10 must exceed the negative selection resulting 
from an increased immunogenic profile. To date, there is no 
evidence that cmvIL-10 drift has resulted in acquisition of 
new functionalities beyond those of cIL-10 [18]. It should 
be emphasized that this refers to the full-length cmvIL-10 
protein. Notably, an incompletely spliced variant of vIL-
10 found during latent infection (LAcmv-IL-10) does have 
novel functionalities that are independent of binding to the 
high-affinity IL-10R1 receptor [13, 18, 24]. The strongest 
clue to what might account for the extensive genetic drift 
of cmvIL-10 and rhcmvIL-10 relates to the relative bind-
ing affinities of cmvIL-10 and cIL-10 for the cellular IL-
10R1 receptor. cmvIL-10 has higher binding affinity for 
IL-10R1 than cIL-10, and one possibility is that sequence 
differences between HCMV and RhCMV vIL-10 proteins 
were compensatory changes to differences between human 
and macaque IL-10R1 proteins [25]. One hypothesis that 
remains to be tested is that the ability of vIL-10 to outcom-
pete cIL-10 for IL-10R1 confers greater fitness to HCMV 
and RhCMV than the negative consequences of drifting to 
an immunogenic form of the protein [21, 25].
Emerging evidence for the vIL-10 proteins of both 
HCMV and RhCMV highlights that vIL-10 broadly targets 
innate immune cells. Based on in vitro assays following 
exposure of macrophages (Mφ), peripheral blood mono-
nuclear cells (PBMC), monocyte-derived dendritic cells 
(MDC), and plasmacytoid dendritic cells (PDC) to vIL-10 
[18, 27–32], expression of vIL-10 in vivo should have plei-
otropic immunosuppressive effects on multiple cell types 
(Table 2). It is especially notable that the functionality 
of vIL-10 is directed at key innate cell types, particularly 
monocytes/Mφ, MDC, and PDC, that are links between the 
innate and adaptive immune responses. vIL-10-mediated 
modulation of the functionality of these cells should have 
the effect of directly influencing the quality of the adaptive 
antiviral immune responses.
Based on the functionalities of vIL-10 on the different 
cell types in Table 2, it is proposed that vIL-10, likely in 
conjunction with other viral proteins, exerts a viral adju-
vant-like effect on long-term antiviral immunity. While it 
remains to be determined whether other HCMV proteins 
exert comparable effects on innate cells, the hypothesis 
leads to a model whereby lifelong persistence is initiated 
at the earliest virus–host interactions following primary 
mucosal infection [16, 26]. Support for this comes from 
inoculation of naïve rhesus macaques with the 68-1 strain 
of RhCMV, a fibroblast-adapted strain, and an engineered 
variant of 68-1 in which the rhcmvIL-10 gene had been 
deleted (RhCMV ΔvIL-10) [26]. Prominent distinctions 
were observed in both the acute and long-term immune 
responses, including the extent and cell composition of the 
cellular infiltrate at the site of subcutaneous (SC) inocu-
lation, and the early and long-term anti-RhCMV adap-
tive immune responses. Based on this result, a converse 
approach, i.e., vaccination against rhcmvIL-10, was evalu-
ated to determine to what extent rhcmvIL-10 influences the 
virus–infected host relationship.
Vaccination against rhcmvIL‑10
As noted, rhcmvIL-10 is strongly immunogenic when 
expressed in the context of RhCMV infection [22], estab-
lishing a precedent to immunize macaques with a recom-
binant form of rhcmvIL-10. However, vaccination of naïve 
animals with fully immunosuppressive vIL-10 would likely 
stimulate immune responses very distinct, and likely unde-
sirable, from those induced by vaccination with a non-func-
tional form of rhcmvIL-10. To maximize immunogenicity 
of rhcmvIL-10, minimal alterations were engineered into 
rhcmvIL-10 (2 amino acids) to create a biologically inac-
tive form of the protein, by abrogating binding to IL10R1 
[22, 33]. The specific amino acids that were changed were 
based on the by crystal structures of cIL-10/IL-10R1 and 
cmvIL-10/IL-10R1 complexes [25]. Immunization of 
RhCMV-uninfected macaques by a combined DNA prime/
protein boost immunization strategy stimulated both rhc-
mvIL-10-binding and rhcmvIL-10-neutralizing antibod-
ies that did not exhibit any cross-reactivity with rhesus 
macaque cIL-10 [34]. Vaccinated animals were subse-
quently challenged with the epitheliotropic UCD59 strain 
of RhCMV and evaluated for molecular and immunologi-
cal parameters of infection. The results demonstrated that 
vaccination against a single RhCMV immune-modulating 
protein, rhcmvIL-10, significantly altered viral parameters 
of challenge infection, including reductions locally at the 
site of SC inoculation, and in the frequency and magni-
tude of RhCMV shedding in saliva and urine. This proof-
of-principal study demonstrated for the first time for CMV 
Table 2  Functional activity of vIL-10 on lymphoid cells in vitro
Cell type(s) Phenotype Ref.
Monocytes ↑ Differentiation into inflammatory mac-
rophages
[26]
↓ HLA-DR
↑ CD64, CCR5
PBMC ↓ Mitogen-stimulated proliferation, MHC-I 
and –II
[27, 28]
↓ IFN-γ
Monocytes ↓ IL-6, IL-1α, GM-CSF, TNF-α; MHC class I 
and II
↑ HLA-G
MDC ↓ TNF-α, IL-6 IL-12, Bcl-2, Bcl-XL [29, 30]
↑ cIL-10
PDC ↓ INF-α, IFN-β [31]
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that vaccine-induced neutralization of the functionality of 
a single immune-modulating protein (rhcmvIL-10) confers 
protective efficacy in the absence of vaccine-induced anti-
bodies that neutralize viral attachment to susceptible cells. 
Extrapolating from this result in macaques to human, vac-
cination against cmvIL-10 should have comparable efficacy 
in protecting against primary HCMV challenge and the 
establishment of a persistent infection. In addition, vacci-
nation could also protect against the maintenance of per-
sistence, based on recent studies on cmvIL-10 expression 
during latency.
IL‑10 signaling during latency
It is well established that HCMV establishes a latent 
infection in CD34+ hematopoietic progenitor cells [35], 
and recent studies indicate that persistence is maintained, 
in part, through HCMV-induced generation of CD4+ T 
cells that secrete cIL-10 in response to HCMV antigens. 
Two hallmarks of latency in these cells are an extremely 
restricted pattern of viral gene expression and the absence 
of infectious virion production [36, 37]. The viral tran-
scriptome defining latently infected CD34+ cells includes 
cmv-IL-10 [24] and LAcmv-IL-10 [38], the aberrantly 
spliced transcript that results in a truncated, but biologi-
cally functional, form of cmvIL-10 that does not engage 
IL-10R1 [39, 40]. Expression of LAcmv-IL-10 in latently 
infected CD34+ cells stimulates expression of cIL-10 in 
a mechanism that appears to involve suppressed expres-
sion of the microRNA hsa-miR-92a [38]. The authors 
note that expression of LAcmv-IL-10 in a paracrine and/
or autocrine fashion “modulates the microenvironment of 
the infected cell, leading to evasion of the immune sys-
tem”. They further speculate that LAcmv-IL-10 represents 
a potential therapeutic target since LAcmv-IL-10 is very 
distinct in sequence from cIL-10. The limited expression 
of the HCMV proteome in latently infected cells also elic-
its a very specific effect on the type of antigen-specific T 
cells. Expression of cmvIL-10, like that of LUNA, UL138, 
and US28, stimulates antigen-specific CD4+ T cells that 
secrete cIL-10 in response to antigen exposure, leading to 
the suggestion that “HCMV skews the T cell responses to 
latency-associated antigens to one that is overall suppres-
sive in order to sustain latent carriage in vivo” [41]. Viral 
induction of cIL-10 signaling parallels MCMV-mediated 
induction of CD4+ T cells secreting cIL-10 [42], lend-
ing support to the hypothesis that disruption of the cIL-
10 signaling pathway in persistent infections may be one 
way of altering the virus–host homeostasis in persistently 
infected hosts to a state favoring host immune-mediated 
clearance of virally infected cells [16]. The mechanisms 
that HCMV appears to utilize in skewing host immune 
responses during a persistent infection may also be opera-
tive during reinfection.
It is now accepted that HCMV can reinfect those with 
prior immunity, which assumes clinical importance in the 
context of congenital infections in populations with near 
universal HCMV seroprevalence [43–47]. Despite the 
extraordinarily large T cell response devoted to HCMV 
antigens and the broad neutralizing responses against 
multiple HCMV glycoproteins involved in attachment 
and entry [9, 48–52], HCMV can reinfect immunocom-
petent individuals with preexisting immunity to HCMV. 
At this point, there is no evidence indicating that reinfec-
tion involves selection for distinctly antigenically variant 
strains of HCMV, which leaves the hypothesis that modula-
tion of host immunity during reinfection enables the rein-
fecting strain to disseminate the mucosal surface to distal 
sites, particularly the maternal/fetal interface. While studies 
investigating the role the vIL-10 may play during HCMV 
and RhCMV reinfection are ongoing, results from the rhe-
sus model unequivocally demonstrate that modulation of 
host immunity is essential for RhCMV reinfection.
Attenuation of host immunity during RhCMV 
reinfection
Rhesus CMV (RhCMV) encodes sequence and functional 
orthologs of HCMV US2, 3, 6, and 11, and like their 
HCMV counterparts, the RhCMV proteins disrupt antigen 
presentation by major histocompatibility complex (MHC) 
class I [53]. The RhCMV orthologs of US2-11 are not 
required for the establishment of a persistent infection fol-
lowing SC inoculation of RhCMV-uninfected macaques 
with an engineered variant of 68-1, in which the RhCMV 
US2-11 orthologs were deleted, and the SIV gag gene was 
coexpressed [54]. Animals developed long-term RhCMV- 
and Gag-specific T cell responses, and input virus could 
be recovered from the urine of inoculated animals almost 
2 years after primary inoculation. However, when animals 
with preexisting immunity to RhCMV were inoculated 
with the same US2-11-deleted variant (and co-expressing 
SIV gag), there was absolutely no evidence of reinfec-
tion. Animals did not develop Gag-specific T cell immune 
responses, and the input virus was never recovered from the 
urine. In contrast, inoculation of immune animals with the 
parental construct expressing US2-11 efficiently resulted 
in reinfection. This study emphasizes that in this model, 
antigenic variation is not the critical factor for reinfection. 
Rather, attenuation of host antiviral immune responses, in 
this case through disruption of MHC class I antigen presen-
tation, is essential for reinfection.
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Summary
Taken as a whole, accumulating data on the immune-modu-
lating proteins of HCMV and RhCMV highlight their cen-
tral role during all phases of the infectious cycle within an 
infected host, beginning with the immediate virus-mediated 
modulation of host immune responses at the mucosal surface 
of a naïve host, to maintenance of an immune suppressive 
environment in latently infection CD34+ cells, to suppres-
sion of effector/memory responses during reinfection of an 
immune host. HCMV has had eons to optimize an orches-
trated symphony of viral functions that target almost every 
aspect of innate and adaptive immunity that we as hosts can 
throw against it. Because of this, HCMV immune modulation 
represents an opportunity to leverage some of these qualities 
to change human health. The dramatic and extremely prom-
ising results obtained using RhCMV-based vaccine vectors 
to protect against virulent SIV challenge are possible only 
because of RhCMV-encoded immune modulatory proteins 
[55–57]. These functions enable reinfection of and long-term 
persistence in immune animals, facilitating long-term, non-
classical CD8+ T cell responses that can protect against SIV 
challenge years after immunization. However, this armada of 
immune-modulating functions constitutes a significant chal-
lenge to overcome in designing vaccine strategies that pre-
vent primary and non-primary infections. Taking Hanshaw’s 
declaration for “any thoughtful program designed at preven-
tion” [58] to heart, the weight of evidence points to some of 
the viral immune-modulating proteins as especially suscepti-
ble targets of the viral proteome for vaccine strategies.
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